Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 18/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 15/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 14/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 14/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 14/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 14/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 14/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 14/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 14/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 14/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5279352 | 0.93 | HDAC6 (0.62) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL5283740 | 0.91 | HDAC1 (0.58) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL5295702 | 0.91 | HDAC6 (0.58) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL6038042 | 0.90 | HDAC6 (0.67) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL5293181 | 0.90 | HDAC6 (0.57) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL5283939 | 0.90 | HDAC6 (0.60) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL5286647 | 0.90 | HDAC6 (0.57) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL6038080 | 0.89 | HDAC6 (0.56) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL5277766 | 0.88 | HDAC6 (0.57) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL5284679 | 0.86 | HDAC6 (0.57) | HDAC6HDAC1HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863804-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2007-12-12 | — | — | EP | claimed |
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | claimed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | claimed |
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | HDAC6 17/4885HDAC1 1/4885HDAC3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.